ELEV
Elevation Oncology Inc

1,330
Loading...
Loading...
News
all
press releases
Allogene's Q1 Earnings In Line With Estimates, Sales Nil
Zacks·5mo ago
News Placeholder
More News
News Placeholder
Elevation Oncology downgraded as it halts lead asset on disappointing trials
Investing.com -- Wall Street cut rating on Elevation Oncology Inc (NASDAQ:ELEV) after the company announced it will discontinue development of its lead asset, EO-3021, due to disappointing efficacy in a Phase 1 trial. Analysts now see limited near-term catalysts, with Elevation pivoting to its HER3-targeted ADC, EO-1022, which is still in preclinical development.
investing.com·6mo ago
News Placeholder
Elevation Oncology to Participate in Upcoming Investor Conferences
Elevation Oncology to Participate in Upcoming Investor Conferences Elevation Oncology to Participate in Upcoming Investor Conferences PR Newswire BOSTON, Feb. 25, 2025 BOSTON, Feb. 25, 2025...
PR Newswire·7mo ago
News Placeholder
Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year
Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year PR Newswire VANCOUVER, BC, Jan. 15, 2025 Issued on behalf...
PR Newswire·9mo ago
News Placeholder
Elevation Oncology Provides Updates on Differentiated ADC Programs and Upcoming Milestones
Elevation Oncology Provides Updates on Differentiated ADC Programs and Upcoming Milestones Elevation Oncology Provides Updates on Differentiated ADC Programs and Upcoming Milestones PR Newswire...
PR Newswire·9mo ago
News Placeholder
Elevation Oncology Expands Pipeline with Nomination of EO-1022, a HER3 ADC for the Treatment of HER3-expressing Solid Tumors
Elevation Oncology Expands Pipeline with Nomination of EO-1022, a HER3 ADC for the Treatment of HER3-expressing Solid Tumors Elevation Oncology Expands Pipeline with Nomination of EO-1022, a HER3 ADC...
PR Newswire·10mo ago
News Placeholder
Elevation Oncology Presents Preclinical Proof-of-Concept Data Supporting Combination Potential of EO-3021 with VEGFR2 or PD-1 Inhibitors at ESMO Immuno-Oncology Annual Congress 2024
Elevation Oncology Presents Preclinical Proof-of-Concept Data Supporting Combination Potential of EO-3021 with VEGFR2 or PD-1 Inhibitors at ESMO Immuno-Oncology Annual Congress 2024 Elevation...
PR Newswire·10mo ago
News Placeholder
Elevation Oncology to Present at the Piper Sandler 36th Annual Healthcare Conference
Elevation Oncology to Present at the Piper Sandler 36th Annual Healthcare Conference Elevation Oncology to Present at the Piper Sandler 36th Annual Healthcare Conference PR Newswire BOSTON, Nov. 26...
PR Newswire·10mo ago
News Placeholder
Elevation Oncology Receives Fast Track Designation from the FDA for EO-3021 for the Treatment of Adult Patients with Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Expressing Claudin 18.2
Elevation Oncology Receives Fast Track Designation from the FDA for EO-3021 for the Treatment of Adult Patients with Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Expressing...
PR Newswire·1y ago
News Placeholder
Elevation Oncology to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Elevation Oncology to Present at the H.C. Wainwright 26th Annual Global Investment Conference Elevation Oncology to Present at the H.C. Wainwright 26th Annual Global Investment Conference PR Newswire...
PR Newswire·1y ago

Latest ELEV News

View

Advertisement|Remove ads.

Advertisement|Remove ads.